

THE LANCET

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: COVID-19 Clinical Research Coalition. Global coalition to accelerate COVID-19 clinical research in resource-limited settings. *Lancet* 2020; published online April 2. [http://dx.doi.org/10.1016/S0140-6736\(20\)30798-4](http://dx.doi.org/10.1016/S0140-6736(20)30798-4).

Members of the COVID-19 Clinical Trials Coalition include:

Noor Hisham Abdullah, Ministry of Health, Malaysia; Marcelo Claudio Abril, Mundo Sano Foundation, Argentina; Ashenafi Tazebew Amare, University of Gondar, Ethiopia; John H Amuasi, the African coalition for Epidemic Research, Response and Training (ALERRT), Ghana; Prasert Auewarakul, Mahidol University, Thailand; Augustin Augier, ALIMA, France; Manica Balasegaram, GARDP, Switzerland; Emmanuel Baron, Epicentre, France; Elsa Baumeister, National Administration of Laboratories and Health Institutes of Argentina (ANLIS), Argentina; Daniel G. Bausch, UK Public Health Rapid Support Team & London School of Hygiene & Tropical Medicine, UK; Philip Bejon, KEMRI-Wellcome Trust Research Programme, Kenya; Anders Björkman, Karolinska Institutet, Sweden; Catharina Boehme, Foundation for Innovative New Diagnostics (FIND), Switzerland; Maria Elena Botazzi, Baylor College of Medicine, USA; Joel G Breman, American Society of Tropical Medicine and Hygiene (ASTMH), USA; Pedro Cahn, Huesped Foundation, Argentina; Gail Carson, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), UK; Roberto Chuit, Argentina National Academy of Health, Argentina; John Clemens, icddr, Bangladesh; Stewart Cole, Pasteur Institute, France; Nick Day, Mahidol Oxford Tropical Medicine Research Unit, Thailand; Arjen Dondorp, Critical Care Asia Network, Mahidol Oxford Tropical Medicine Research Unit, Thailand; Paul Farmer, Harvard Medical School, USA; Jeremy Farrar, Wellcome, UK; Abebaw Fekadu, CDT-Africa, Addis Ababa University, Ethiopia; Antoine Flahault, Institute of Global Health, University of Geneva, Switzerland; Patricia Garcia, Universidad Peruana Cayetano Heredia, Peru; Steven Gordon, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Malawi; Anastasia Guantai, University of Nairobi, Kenya; Philippe J Guerin, Infectious Diseases Data Observatory (IDDO), University of Oxford, UK; Abraham Hodgson, Ghana Health Service, Ghana; Peter Horby, ISARIC & the African Coalition for Epidemic Research, Response and Training (ALERRT), UK; Peter Hotez, Baylor College of Medicine, USA; Muntaser Ibrahim, Institute of Endemic Diseases, University of Khartoum, Sudan; Chikwe Ihekweazu, Nigeria Centre for Disease Control, Nigeria; Timo Jaeger, DZIF German Center for Infection Research, Germany; Jean Jannin, Société Francophone de Médecine Tropicale et Santé Internationale, France; Gagandeep Kang, Translational Health Science and Technology Institute of India, India; Marie-Paule Kieny, Drugs for Neglected Diseases *initiative* (DNDi), Switzerland; Yeri Kombe, KEMRI, Kenya; Hans-Georg Kraeusslich, DZIF German Center for Infection Research,

Germany; David Lalloo, Liverpool School of Tropical Medicine, UK; Trudie Lang, The Global Health Network, UK; Ramanan Laxminarayan, Center for Disease Dynamics, Economics & Policy, USA; Honorati Masanja, Ifakara Health Institute, Tanzania; Marcela Mercado, Instituto Nacional de Salud de Colombia, Colombia; Hassan Mshinda, Botnar Foundation, Tanzania; Joia Mukherjee, Partners in Health, USA; Trevor Mundel, Bill & Melinda Gates Foundation, USA; Jean-Jacques Muyembe, Institut National pour la Recherche Biomédicale, Democratic Republic of Congo; Barnabas Nawangwe, Makerere University, Uganda; Francine Ntoumi, Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Disease Epidemics (PANDORA-ID-NET) and Fondation Congolaise pour la Recherche Médicale, Republic of Congo; Marta Ospina, Instituto Nacional de Salud de Colombia, Colombia; Michael Parker, ETHOX Centre, University of Oxford, UK; Bernard Pécou, Drugs for Neglected Diseases *initiative* (DNDi), Switzerland; Antonio Plasència Taradach, ISGlobal, Spain; Richard Price, Menzies School of Health Research, Australia; David Reddy, Medicines for Malaria Venture, Switzerland; John Reeder, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Switzerland; Philip J Rosenthal, UCSF, USA; John Arne Røttingen, Norwegian Research Council, Norway; Fred Siyoi, Kenya Pharmacy & Poisons Board, Kenya; Munir S. Skaf, University of Campinas, Brazil; Nathalie Strub-Wourgaft, Drugs for Neglected Diseases *initiative* (DNDi), Switzerland; Marcel Tanner, Swiss Academy of Arts and Sciences, Switzerland; Guy Thwaites, Oxford University Clinical Research Unit, Vietnam; Faustino Torrico, CEADES Foundation, Bolivia; Nísia Trindade Lima, Fundação Oswaldo Cruz (Fiocruz), Brazil; Jürg Utzinger, Swiss Tropical and Public Health Institute, Switzerland; George M Varghese, Christian Medical College, Vellore, India; Nicholas J. White, Mahidol Oxford Tropical Medicine Research Unit, Thailand; Marc-Alain Widdowson, Institute of Tropical Medicine, Belgium; Charles S Wiysonge, South African Medical Research Council, South Africa; Tassew Woldehanna, Addis Ababa University, Ethiopia; Katharine Wright, Nuffield Council of Bioethics, UK; Yazdan Yazdanpanah, REACTing & INSERM, France.